1. Home
  2. EOS vs MNKD Comparison

EOS vs MNKD Comparison

Compare EOS & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Enhance Equity Income Fund II

EOS

Eaton Vance Enhance Equity Income Fund II

N/A

Current Price

$19.78

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Logo MannKind Corporation

MNKD

MannKind Corporation

N/A

Current Price

$3.92

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EOS
MNKD
Founded
N/A
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2004
2004

Fundamental Metrics

Financial Performance
Metric
EOS
MNKD
Price
$19.78
$3.92
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $8.08
AVG Volume (30 Days)
147.5K
★ 3.4M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $348,966,000.00
Revenue This Year
N/A
$26.63
Revenue Next Year
N/A
$14.81
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 22.23
52 Week Low
$19.44
$2.23
52 Week High
$23.62
$6.51

Technical Indicators

Market Signals
Indicator
EOS
MNKD
Relative Strength Index (RSI) 33.55 64.58
Support Level $19.44 $3.77
Resistance Level $21.69 $3.94
Average True Range (ATR) 0.29 0.17
MACD -0.08 0.09
Stochastic Oscillator 10.07 82.50

Price Performance

Historical Comparison
EOS
MNKD

About EOS Eaton Vance Enhance Equity Income Fund II

Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: